HitGen Inc., (SHA: 688222) a China-based pharmaceutical company, has announced that the Investigational New Drug (IND) filing for its Lipisense (A24110He for injection) has received approval from China’s Center for Drug Evaluation (CDE). Lipisense, an innovative antisense oligonucleotide (ASO) drug originally developed by Swiss firm Lipigon Pharmaceuticals AB, is designed to significantly reduce triglyceride levels and enhance insulin resistance. This drug aims to offer improved treatment options for patients with dyslipidemia, particularly those with severe hypertriglyceridemia.
The drug’s development has been supported by positive results from a Phase I clinical study in Europe, which showed good safety, tolerability, and early signs of efficacy. A Phase II trial is on the verge of commencement in the region. HitGen had been providing research and development support to Lipigon in the identification of drugs within the cardiometabolic space since a partnership was first announced in 2020. HitGen holds the rights for Lipisense in Greater China.- Flcube.com
